公开(公告)号：US10933134B2

公开(公告)日：2021-03-02

申请号：US15924039

申请日：2018-03-16

Applicant: Memorial Sloan Kettering Cancer Center ,  Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science

Inventor： Jonathan Coleman ,  Philip A. Watson ,  Kwanghee Kim ,  Avigdor Scherz

IPC: A61K41/00 ,  A61P35/00 ,  A61K31/4166 ,  A61K38/08 ,  A61K47/64 ,  A61N5/06

Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

公开(公告)号：US20170143988A1

公开(公告)日：2017-05-25

申请号：US15425473

申请日：2017-02-06

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor Scherz ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

IPC: A61N5/06 ,  C07F15/00 ,  A61K49/00 ,  C07F3/06 ,  C07F13/00 ,  A61K41/00 ,  A61F9/00 ,  C07F1/08

CPC classification number: A61N5/062 ,  A61F9/0008 ,  A61K31/40 ,  A61K41/0071 ,  A61K41/0076 ,  A61K49/0036 ,  A61N5/0624 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F13/005 ,  C07F15/006 ,  C07F15/0066 ,  C07F15/045

Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

公开(公告)号：US20250082957A1

公开(公告)日：2025-03-13

申请号：US18726614

申请日：2023-01-05

Applicant: STEBA BIOTECH S.A. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zachary Sacks ,  Yaniv Cohen ,  Avigdor Scherz

IPC: A61N5/06

Abstract: An assembly, system, and method for photodynamic therapy (PDT) of a target tissue utilizing a delivery apparatus and a displacement control arrangement. The delivery apparatus comprises a flexible needle device with an elongated flexible tube having a fiber-receiving lumen, extendable in a proximal-distal direction along a delivery axis, and with a pointed, needle-like distal tip for penetrating said tissue. An optical fiber is insertable and axially displaceable within said lumen and couplable at its proximal end to a light source, emitting a PDT-effective light at a wavelength applicable for said PDT. The fiber's distal end portion has a light-diffusing section for emitting light from within the fiber in one or more directions and has one or more X-ray markers. The displacement-control arrangement is couplable to a proximal portion of the flexible needle device and to a proximal portion of the optical fiber accommodated within the flexible needle device with the proximal portion projecting out of the proximal end of the flexible needle device, and comprises an axial displacement arrangement configured for controlled axial displacement of said delivery apparatus. The delivery apparatus may also comprise a delivery catheter extending in a proximal-to-distal direction and has a working channel that can accommodate the flexible needle device.

公开(公告)号：US11278555B2

公开(公告)日：2022-03-22

申请号：US16092742

申请日：2017-04-10

Applicant: Yeda Research and Development Co. Ltd. ,  Memorial Sloan-Kettering Cancer Center

Inventor： Avigdor Scherz ,  Yoram Salomon ,  Lilach Agemy ,  Rachel Hamri ,  Dina Preise ,  Kwanghee Kim ,  Jonathan Coleman

IPC: A61K31/675 ,  A61K31/409 ,  A61K31/7068 ,  A61K31/7135 ,  A61K45/06 ,  A61P35/00

Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).

公开(公告)号：US11058772B2

公开(公告)日：2021-07-13

申请号：US16196537

申请日：2018-11-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor Scherz ,  Yoram Salomon ,  Arie Marcovich ,  Alexander Brandis ,  Daniel Wagner

IPC: A61K31/407 ,  A61K41/00 ,  A61K31/555 ,  A61K9/00 ,  A61K31/519 ,  A61K47/36 ,  A61N5/06

Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.

公开(公告)号：US09796763B2

公开(公告)日：2017-10-24

申请号：US14093562

申请日：2013-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor Scherz ,  Oksana Shlyk-Kerner ,  Ilan Samish ,  David Kaftan ,  Jorge Dinamarca

IPC: C12N15/00 ,  C12N15/05 ,  A61K35/748 ,  C07K14/405 ,  C07K14/195 ,  A61K38/00

CPC classification number: C07K14/405 ,  C07K14/195

Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.